Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MULTIBENZ: Benznidazole regimens for chronic Chagas disease
NCT03191162Phase 2Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of benznidazole in Chagas disease (3 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of patients with negative parasitaemia measured by PCR at 12 months. Started Apr 2017; status: completed.
02
Drugs
benznidazole
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT03191162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191162.